<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Metronidazole: An overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Metronidazole: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Metronidazole: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melissa Johnson, PharmD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Hooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is one of the mainstay drugs for the treatment of anaerobic infections [<a href="#rid1">1,2</a>]. It is approved by the US Food and Drug Administration for the treatment of anaerobic and protozoal infections. Metronidazole exerts its antimicrobial effects through the production of free radicals that are toxic to the microbe.</p><p>The use of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> for treating specific infections is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5520.html" rel="external">"Anaerobic bacterial infections"</a> and  <a class="medical medical_review" href="/z/d/html/2698.html" rel="external">"<i>Clostridioides difficile</i> infection in adults: Treatment and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/5727.html" rel="external">"Intestinal Entamoeba histolytica amebiasis"</a> and  <a class="medical medical_review" href="/z/d/html/5728.html" rel="external">"Extraintestinal Entamoeba histolytica amebiasis"</a> and  <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">"Trichomoniasis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span>Activity against most obligate anaerobes occurs through a four-step process:</p><p class="bulletIndent1"><span class="glyph">●</span>Entry into the microorganism – <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is a low molecular weight compound that diffuses across the cell membranes of anaerobic and aerobic microorganisms. However, antimicrobial activity is limited to anaerobes [<a href="#rid3">3</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reductive activation by intracellular transport proteins – <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is reduced by the pyruvate:ferredoxin oxidoreductase system in obligate anaerobes, which alters its chemical structure. Pyruvate:ferredoxin oxidoreductase normally generates adenosine triphosphate (ATP) via oxidative decarboxylation of pyruvate. With metronidazole in the cellular environment, its nitro group acts as an electron sink, capturing electrons that would usually be transferred to hydrogen ions in this cycle. Reduction of metronidazole creates a concentration gradient that drives uptake of more drug and promotes formation of intermediate compounds and free radicals that are toxic to the cell [<a href="#rid3">3-5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced intermediate particle interacts with intracellular targets – Cytotoxic-intermediate particles interact with host cell deoxyribonucleic acid (DNA), resulting in DNA strand breakage and fatal destabilization of the DNA helix [<a href="#rid6">6,7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breakdown of cytotoxic-intermediate products – The toxic-intermediate particles decay into inactive end products [<a href="#rid8">8</a>].</p><p></p><p><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is also cytotoxic to facultative anaerobic bacteria such as <em>Helicobacter pylori</em> and <em>Gardnerella vaginalis</em>, but the mechanism of this action is not well understood [<a href="#rid3">3</a>]. Metronidazole exerts rapid bactericidal effects against anaerobic bacteria with a killing rate proportional to the drug concentration [<a href="#rid9">9,10</a>]. Concentration-dependent killing has also been observed with <em>Entamoeba histolytica</em> and <em>Trichomonas vaginalis </em>[<a href="#rid11">11,12</a>]. Metronidazole kills <em>Bacteroides fragilis</em> and <em>Clostridium perfringens </em>more rapidly than <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a> [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/485.html" rel="external">"Clindamycin: An overview"</a>.)</p><p>No apparent antagonism exists between <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> and other antimicrobial agents, such as <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, and ticarcillin, against strains of <em>B. fragilis</em> [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H3"><span class="h1">RESISTANCE</span><span class="headingEndMark"> — </span>Despite extensive worldwide use, acquired resistance to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> among anaerobic bacteria is rare.</p><p class="headingAnchor" id="H4"><span class="h2">Anaerobes</span><span class="headingEndMark"> — </span>Surveys demonstrate that more than 95 percent of anaerobic isolates in the United States are susceptible to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid15">15,16</a>]. Among <em>Bacteroides</em> spp, one large multicenter study of more than 4000 strains collected over a seven-year period in the 1990s revealed no isolates resistant to metronidazole [<a href="#rid17">17</a>]. A second survey during that time period also found no resistance in 542 bloodstream <em>B. fragilis</em> isolates from 12 United States medical centers [<a href="#rid18">18</a>]. Through 2007, only three metronidazole-resistant cases were reported in United States surveillance studies [<a href="#rid19">19</a>]. Subsequently, metronidazole-resistant <em>B. fragilis</em> infections in the United States have been described in several case reports [<a href="#rid20">20-22</a>]. The organisms were resistant to multiple other antibiotics in addition to metronidazole. Affected patients had either traveled or were hospitalized internationally, which may have contributed to acquisition of these resistant <em>B. fragilis</em> strains.</p><p>Outside the United States, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> resistance among gram-negative anaerobes has been reported more frequently and appears to be rising in some countries such as India [<a href="#rid23">23</a>]. Resistance rates vary by country but are generally low in most countries. Predictions were made that the incidence of metronidazole resistance would rise with increased use of the drug for the treatment of antibiotic-associated colitis [<a href="#rid24">24</a>]. However, a study from France compared <em>Clostridioides</em> <em>difficile</em> isolates from 1991 and 1997 and found no increase in minimum inhibitory concentration (MIC) to metronidazole or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> among these strains [<a href="#rid25">25</a>].</p><p>In <em>Bacteroides</em> species, resistance has been conferred by both plasmid- and chromosomally mediated mechanisms, although plasmid-mediated transfer of resistance to susceptible strains has been rare [<a href="#rid26">26</a>]. Multiple steps appear necessary for resistance to develop, which may explain why resistance is rare in the absence of long-term therapy [<a href="#rid27">27</a>]. Resistance is conferred through a reduction in pyruvate:ferredoxin oxidoreductase activity, which limits cellular uptake of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> and subsequent activation. The level of susceptibility and rate of drug uptake varies with the level of pyruvate:ferredoxin oxidoreductase activity. Resistant bacteria compensate for reduced action of pyruvate:ferredoxin oxidoreductase by increasing lactate dehydrogenase activity [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Helicobacter pylori</span><span class="headingEndMark"> — </span>Although development of resistance to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> in anaerobic bacteria is rare, it has been reported more frequently with <em>H. pylori</em> [<a href="#rid29">29,30</a>]. A systematic review of 19 studies performed in the United States found that more than 30 percent of <em>H. pylori</em> isolates were resistant to metronidazole [<a href="#rid31">31</a>]. Data regarding the mechanism of resistance to metronidazole are evolving. Mutations in the <em>rdxA</em> gene, which encodes an enzyme that activates the drug, may result in resistant strains of <em>H. pylori. </em>Mutations in other redox genes such as <em>frxA</em> may also contribute to resistance synergistically in the presence of <em>rdxA</em> mutations [<a href="#rid32">32</a>].<em> </em>Other mechanisms may also contribute to resistance, such as reduced uptake or efflux of metronidazole [<a href="#rid33">33-35</a>]. </p><p>Several reports have documented the development of resistance and subsequent clinical failure among patients receiving <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> for <em>H. pylori</em> infections [<a href="#rid36">36,37</a>]. One study found that eradication rates among 196 patients with <em>H. pylori</em> infection were significantly lower for metronidazole-resistant strains than metronidazole-susceptible strains (67 versus 87 percent) [<a href="#rid38">38</a>]. A meta-analysis of 49 studies found that resistance to metronidazole decreased the efficacy of treatment by a mean of 38 percent, but there was significant heterogeneity in the results [<a href="#rid39">39</a>]. The outcome was more dramatic for <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a> resistance, although the number of studies available for analysis was fewer.</p><p class="headingAnchor" id="H6"><span class="h2">Trichomonas vaginalis</span><span class="headingEndMark"> — </span>Resistant <em>T. vaginalis</em> strains have been isolated from patients with refractory trichomonal infections [<a href="#rid40">40-42</a>]. In these organisms, the pyruvate:ferredoxin oxidoreductase protein is contained in a hydrogenosome, since the organism lacks mitochondria [<a href="#rid43">43</a>]. Resistance to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is associated with reduced transcription activity of the ferredoxin gene that results in decreased intracellular levels of ferredoxin and reduced pyruvate:ferredoxin oxidoreductase activity. In addition, oxidation of pyruvate to lactate within hydrogenosomes is terminated and occurs instead in the cytosol via lactate dehydrogenase [<a href="#rid44">44,45</a>]. (See  <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">"Trichomoniasis: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Susceptibility testing</span><span class="headingEndMark"> — </span>Susceptibility testing for anaerobic bacteria is not routinely performed in clinical laboratories since it is cumbersome and not well standardized. However, testing may be indicated for certain serious infections, including brain abscess, endocarditis, osteomyelitis, arthritis, prosthetic device or vascular graft infection, and refractory or recurrent bacteremia. Testing might also be useful for persistent infections, for infections in which medical rather than surgical therapy is chosen, and for those in which prolonged therapy is anticipated. The Clinical Laboratory Standards Institute (formerly called the National Committee for Clinical Laboratory Standards) has established for anaerobes a breakpoint of 8 mcg/mL for susceptibility, 16 mcg/mL for intermediate susceptibility, and ≥32 mcg/mL for resistance to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>.</p><p>The primary benefit of susceptibility testing is not to document susceptibility but rather to demonstrate unexpected resistance to an antimicrobial that is normally useful. Many clinicians will request anaerobic susceptibility testing from a reference laboratory when a patient has not responded clinically to an appropriate regimen directed at anaerobes. While awaiting the results of this testing, the patient should be changed to a different empiric therapy.</p><p>The clinical relevance of documented bacterial resistance in the setting of mixed anaerobic infections remains unclear. Other factors, including surgical debridement and the presence of comorbidities, significantly affect treatment outcomes. One prospective multicenter study assessed mortality, clinical treatment failure, and microbiologic persistence in 128 patients with <em>Bacteroides</em> bacteremia; susceptibility testing was performed on all isolates [<a href="#rid46">46</a>]. All of the outcome measures were worse for patients who received drugs that were not active against the organism compared with those with susceptible isolates (45 versus 16 percent 30-day mortality; 82 versus 22 percent clinical failure; and 47 versus 12 percent microbiologic persistence). No isolates were resistant to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> in this study.</p><p class="headingAnchor" id="H8"><span class="h1">SPECTRUM OF ACTIVITY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is active against a broad array of anaerobes, protozoa, and microaerophilic bacteria.</p><p class="headingAnchor" id="H74244815"><span class="h2">Anaerobes</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> exerts potent bactericidal activity against anaerobic gram-negative organisms such as <em>Bacteroides</em> spp, <em>Prevotella</em> spp, <em>Porphyromonas</em> spp, <em>Fusobacterium</em> spp, <em>Bilophila wadsworthia</em>, and<em> Capnocytophaga</em> [<a href="#rid47">47-49</a>]. Anaerobic cocci such as <em>Peptostreptococcus</em> and <em>Veillonella </em>species are also inhibited by metronidazole.</p><p><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is active against the anaerobic gram-positive bacilli of <em>Clostridium</em> spp, although <em>Clostridium ramosum</em> may require higher concentrations of the drug for inhibition [<a href="#rid50">50,51</a>]. Among gram-positive anaerobic bacilli, metronidazole activity is generally lower or variable. Seventy-five percent of <em>Actinomyces</em> spp, <em>Propionibacterium propionica</em>, <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>)<em> acnes</em>, and <em>Lactobacillus </em>species are resistant to metronidazole [<a href="#rid48">48-52</a>]. Susceptibility of <em>Mobiluncus</em> is variable; <em>Mobiluncus curtisii </em>is usually resistant to metronidazole, whereas <em>Mobiluncus mulieris</em> is often susceptible [<a href="#rid53">53,54</a>].</p><p class="headingAnchor" id="H764811175"><span class="h2">Other organisms</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is also active against anaerobic protozoa such as <em>T. vaginalis</em>, <em>E. histolytica</em>, <em>Giardia lamblia</em>, <em>Blastocystis hominis</em>, and <em>Balantidium coli</em>. <em>G. vaginalis</em> and <em>Actinobacillus actinomycetemcomitans</em> are usually susceptible to the parent compound; the hydroxy metabolite of metronidazole is two to eight times more active against these organisms [<a href="#rid55">55,56</a>]. Activity of metronidazole against<em> H. pylori</em> varies. (See <a class="local">'Helicobacter pylori'</a> above.)</p><p class="headingAnchor" id="H9"><span class="h1">PHARMACOKINETICS</span><span class="headingEndMark"> — </span>Two of the hallmarks of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> are that the drug achieves high serum concentrations following oral administration and that its tissue penetration is excellent.</p><p class="headingAnchor" id="H10"><span class="h2">Systemic metronidazole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is well absorbed after oral administration and is virtually 100 percent bioavailable [<a href="#rid57">57</a>].</p><p><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> generally distributes well into body tissues and, unlike <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, effectively penetrates the blood-brain barrier. In patients without meningeal inflammation, cerebrospinal fluid (CSF) levels approximate 45 percent of corresponding serum concentrations [<a href="#rid58">58</a>]. Patients with meningitis experience similar CSF and serum concentrations. Metronidazole exhibits excellent penetration into brain abscesses, where concentrations approximate that in serum [<a href="#rid59">59</a>]. Metronidazole also distributes well into muscle tissue of patients with sepsis or those undergoing surgery [<a href="#rid60">60,61</a>].</p><p><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is minimally protein bound, with approximately 80 percent or more circulating as free drug. Concentrations sufficient for therapeutic activity are achieved in hepatic abscesses as well as alveolar bone. Among patients with common bile duct obstruction, metronidazole concentrations in the common bile duct following intravenous administration were reportedly 56 to 99 percent that of serum. Among patients with gallstones but preserved gallbladder function and among those with absent gallbladder function but a patent cystic duct, metronidazole concentrations in the gallbladder bile, common duct bile, and serum were similar. By contrast, little to no metronidazole was recovered from gallbladder bile among patients who had a stone blocking the cystic duct [<a href="#rid62">62</a>].</p><p><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> exhibits a dose-dependent metabolism and is metabolized in the liver to glucuronide-conjugated and oxidative products, including a hydroxy-metabolite, which has 30 to 65 percent of the activity of the parent compound [<a href="#rid63">63</a>]. Six to 18 percent of metronidazole is excreted unchanged in urine; the metabolites are also excreted in the urine.</p><p>The half-life of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> in patients with normal renal function is six to nine hours and is unchanged in those with renal insufficiency. Some studies have demonstrated that elimination of metronidazole metabolites may be reduced among those with renal insufficiency, but there are no specific recommendations for dose reduction in this patient population [<a href="#rid64">64</a>]. Hemodialysis may increase the clearance of metronidazole by 100 percent or more, resulting in a shortened half-life of only 2.1 to 3.3 hours [<a href="#rid64">64-67</a>]. The wide therapeutic index of the drug may make dose supplementation necessary only in seriously ill patients. The pharmacokinetics of metronidazole and its metabolites are not appreciably affected by chronic ambulatory peritoneal dialysis, with peritoneal dialysis accounting for only 8.9 percent of total body clearance [<a href="#rid68">68</a>]. However, the half-life of the drug may be extended to 18 to 20 hours in those with hepatic failure [<a href="#rid69">69-80</a>]. The delay in elimination is directly related to the extent of liver impairment.</p><p>The wide therapeutic index and a half-life that approaches 12 hours of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> have prompted some to question whether three times a day dosing for most anaerobic infections is necessary for optimal clinical outcomes. Although a few retrospective studies have demonstrated similar clinical outcomes with twice-daily dosing of metronidazole, further studies are needed to elucidate which patients and/or infections are suitable for lower metronidazole dosing. There are limited data for certain populations and infections so more frequent dosing is still commonly used in pediatrics, central nervous system infections, parasitic/amebic infections, and <em>C. difficile</em> infection. </p><p>In a retrospective, single-center pre- and postintervention study of 200 patients with indications for <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, there were no differences in clinical cure (85 versus 85 percent), mean duration of antibiotic therapy (5.9 versus 5.8 days), or hospital length of stay (8.1 versus 6.7 days) in patients who received twice-daily dosing compared with thrice-daily dosing of metronidazole 500 mg [<a href="#rid81">81</a>]. Patients with <em>C. difficile</em>, parasitic, amebic, and central nervous system infections were excluded from the study, and more than 90 percent of participants received metronidazole empirically and did not appear to have a confirmed anaerobic infection. In another multi-center retrospective study of 85 patients with confirmed anaerobic bacteremia, there was no significant difference in mortality, length of stay, or escalation of therapy in patients receiving twice-daily dosing compared with thrice-daily dosing of metronidazole 500 mg [<a href="#rid82">82</a>]. In vitro studies similarly demonstrated that twice-daily dosing achieved the MICs for most anaerobic organisms (eg, <em>Bacterioides fragilis</em>) [<a href="#rid76">76,83</a>]. </p><p>Among children and adolescents, the pharmacokinetics of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> are similar to those of adults. However, metabolic elimination of metronidazole is significantly decreased among premature neonates, with clearance and half-life correlating with gestational age. Careful dose adjustments are thus recommended for this patient population [<a href="#rid57">57,74,75</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Topically administered metronidazole</span><span class="headingEndMark"> — </span>When applied to the face, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> gel is absorbed systemically to a negligible degree [<a href="#rid76">76</a>]. When administered intravaginally, metronidazole gel is absorbed to varying degrees, depending upon formulation. The commercial 0.75% intravaginal gel produced peak serum concentrations of 0.2 to 0.3 mg/L, which are significantly less than those observed after a single 500 mg oral dose (8 to 13 mg/L) [<a href="#rid76">76</a>]. However, vaginal suppositories have produced slightly higher peak serum concentrations of 1.1 to 1.9 mg/L (approximately 10 percent of concentrations achieved with oral administration) than those with the commercial intravaginal gel [<a href="#rid76">76</a>].</p><p class="headingAnchor" id="H12"><span class="h1">TOXICITY</span><span class="headingEndMark"> — </span>The most common adverse effects associated with systemic <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> therapy are gastrointestinal [<a href="#rid77">77</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Gastrointestinal</span><span class="headingEndMark"> — </span>Gastrointestinal symptoms such as nausea, anorexia, vomiting, diarrhea, abdominal cramping, and constipation have been associated with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>. An unpleasant metallic taste is also often experienced by those taking metronidazole systemically. Furry tongue, glossitis, and stomatitis have also been experienced and are associated with candidal overgrowth. Although the drug is active against <em>C. difficile</em>, cases of <em>C. difficile </em>colitis have been reported rarely among patients receiving metronidazole [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Nervous system</span><span class="headingEndMark"> — </span>Seizures, peripheral neuropathy, dizziness, vertigo, ataxia, confusion, encephalopathy, irritability, weakness, insomnia, headache, and tremors have been reported among patients receiving <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, particularly among those receiving high doses of the drug [<a href="#rid75">75,79,80,84-86</a>]. In some patients, metronidazole neurotoxicity can be visualized on magnetic resonance imaging and is characterized by bilateral symmetric T2 hyperintense lesions that resolve after metronidazole cessation [<a href="#rid87">87</a>]. A randomized trial evaluating metronidazole (500 mg three times daily) for the treatment of pulmonary multidrug-resistant tuberculosis was stopped early due to a high rate of peripheral neuropathy with metronidazole compared with placebo (50 versus 12 percent) [<a href="#rid88">88</a>]. Treatment was stopped at a median of 31 days in 12 patients, and the neuropathies resolved in most patients a median of 1006 days after treatment had been started. There was no correlation between pharmacokinetic measures of metronidazole exposure and peripheral neuropathy. All patients were taking other antituberculosis medications, but these were not described in detail.</p><p class="headingAnchor" id="H15"><span class="h2">Allergic reactions</span><span class="headingEndMark"> — </span>Hypersensitivity reactions have been reported among patients receiving <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> and may include urticaria, erythematous rash, flushing, bronchospasm, and serum sickness [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Genitourinary</span><span class="headingEndMark"> — </span>Transient darkening of the urine to a deep red-brown color is common among patients receiving <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>. Dysuria, cystitis, incontinence, vaginal <em>Candida</em> overgrowth, and decreased libido have also been reported less commonly.</p><p class="headingAnchor" id="H625744346"><span class="h2">Disulfiram-like reactions</span><span class="headingEndMark"> — </span>There have been case reports suggesting a possible disulfiram-like reaction when <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is administered systemically or vaginally to patients drinking ethanol [<a href="#rid90">90-93</a>], but it remains unclear whether metronidazole causes this reaction. The typical disulfiram reaction causes flushing, tachycardia, palpitations, nausea, and vomiting. In a review of cases of disulfiram-like reactions in patients receiving metronidazole published between 1964 and 1999, eight cases were identified [<a href="#rid91">91</a>]. Four of the cases were serious, including one fatality. Reported reactions included flushing, sweating, headache, nausea, vomiting, dyspnea, skin pallor, acidosis, and death. However, the authors of the review noted that, in most of these cases, there were possible alternative explanations for the reactions that were not explored.</p><p>The mechanism of disulfiram-like reactions with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is unknown; unlike disulfiram, metronidazole does not inhibit alcohol metabolism in the liver and does not increase acetaldehyde production. In a study of 12 healthy volunteers, no apparent adverse effects or increase in blood acetaldehyde levels were observed when six individuals received metronidazole 200 mg three times a day for five days followed by a single dose of ethanol 0.4 g/kg (approximately half a standard drink) compared with six individuals who ingested ethanol and placebo [<a href="#rid94">94</a>]. A study reported that rats receiving metronidazole and ethanol concomitantly had an increase in intracolonic acetaldehyde concentrations but not blood acetaldehyde concentrations compared with rats receiving ethanol alone [<a href="#rid95">95</a>]. The investigators suggested that this may be explained by metronidazole's impact on intestinal flora, with conversion to alcohol dehydrogenase-containing anaerobes; the mechanism of the disulfiram-like reaction with metronidazole may therefore be related to changes in gut flora with exposure to this antibiotic. Other studies have suggested that histamine reactions have been associated with similar intracolonic acetaldehyde concentrations, and investigators hypothesize that this could possibly lead to the disulfiram-like reaction with metronidazole [<a href="#rid94">94</a>].</p><p>While clear evidence of a disulfiram-like reaction with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is lacking, the manufacturer's product information recommends avoiding alcohol ingestion during metronidazole therapy and for at least 48 hours afterwards. Without larger studies suggesting safe coadministration of metronidazole and ethanol, concomitant use should be avoided.</p><p class="headingAnchor" id="H17"><span class="h2">Other</span><span class="headingEndMark"> — </span>Less common adverse reactions reported with use of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> include joint pain and thrombophlebitis; hematologic effects such as reversible neutropenia and thrombocytopenia have rarely occurred [<a href="#rid96">96,97</a>]. Several case reports have also documented pancreatitis and hepatitis associated with use of metronidazole, although these events are rare [<a href="#rid98">98,99</a>].</p><p>There have been a few reports of QT interval prolongation with use of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> [<a href="#rid100">100-103</a>]; this may be of particular concern in patients receiving other drugs that prolong the QT interval or when other risk factors are present, particularly congenital prolonged QT syndrome. (See <a class="local">'Drug interactions'</a> below.)</p><p class="headingAnchor" id="H18"><span class="h3">Metronidazole topical (dermatologic) gel</span><span class="headingEndMark"> — </span>Systemic effects are rare with topical application of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> gel, since very little metronidazole is absorbed systemically. Local effects including skin irritation, transient skin erythema, and mild dryness or burning of the skin are uncommon.</p><p class="headingAnchor" id="H19"><span class="h3">Metronidazole vaginal gel</span><span class="headingEndMark"> — </span>Genitourinary effects include symptomatic <em>Candida </em>cervicitis/vaginitis, vaginal, perineal, or vulvar itching, vaginal discharge, and vulvar swelling. Cramps and abdominal or uterine pain have also been reported among women using <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> intravaginally. Nausea, metallic taste, constipation, diarrhea, decreased appetite, dizziness, and headache have been reported less commonly. Increased or decreased white blood counts and rash are rare.</p><p class="headingAnchor" id="H20"><span class="h1">DRUG INTERACTIONS</span><span class="headingEndMark"> — </span>As mentioned above, ingestion of alcohol during <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> therapy can result in a disulfiram-like reaction (see <a class="local">'Disulfiram-like reactions'</a> above). Ethanol-containing medications such as elixirs as well as <a class="drug drug_general" data-topicid="9459" href="/z/d/drug information/9459.html" rel="external">tipranavir</a> capsules, intravenous (IV) <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and many cough/cold syrups may also lead to a disulfiram-like reaction when ingested with metronidazole. In addition, use of metronidazole with disulfiram can result in an acute psychosis or confusional state [<a href="#rid57">57</a>]. Sudden deaths have been attributed to metronidazole/ethanol reactions [<a href="#rid90">90,91</a>].</p><p><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> can promote renal retention of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, resulting in increased lithium levels and lithium toxicity [<a href="#rid104">104,105</a>]. Metronidazole can also decrease elimination of ergot derivatives, so concomitant use of these agents is not recommended.</p><p>Most drug interactions with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> occur in the liver, where metronidazole is metabolized. It has been suggested that metronidazole selectively inhibits aromatic oxidase reactions in the liver, a property that may explain its inhibition of <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> metabolism. Metronidazole decreases the clearance of phenytoin approximately 15 percent and thus prolongs its elimination half-life [<a href="#rid106">106</a>]. This reduced elimination may result in increased serum concentrations of phenytoin. Caution should also be used when administering <a class="drug drug_general" data-topicid="8480" href="/z/d/drug information/8480.html" rel="external">fosphenytoin</a> and metronidazole concomitantly. Metronidazole can increase the anticoagulant effect of warfarin via its S(-)-warfarin stereoisomer [<a href="#rid107">107</a>]. Thus, patients receiving the two agents concomitantly should have prothrombin time monitored closely and warfarin doses adjusted accordingly. One case report of carbamazepine toxicity in a patient five days after initiation of metronidazole suggests a potential drug interaction may also exist between metronidazole and carbamazepine [<a href="#rid108">108</a>].</p><p>Torsades de pointes has been reported rarely when <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> has been used in combination with other drugs that prolong the QT interval or when other risk factors have been present [<a href="#rid102">102,109,110</a>]. As an example, a potential interaction between metronidazole and <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a> in a 71-year-old female appeared to result in QTc prolongation and torsades de pointes [<a href="#rid109">109</a>]. Cytochrome P450-3A4 inhibition by metronidazole may have resulted in increased serum concentrations of amiodarone, leading to marked QT interval prolongation and torsades de pointes. (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p>A few investigators have reported significant increases in <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> and <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> serum concentrations after patients were initiated on <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> therapy [<a href="#rid111">111-113</a>]. However, in a cohort study of 52 adult solid organ transplant recipients with <em>C. difficile </em>infection, there were similar mean elevations in dose-normalized tacrolimus trough levels in patients treated with either metronidazole or <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid114">114</a>]. The observed increase in tacrolimus levels may be related to the effect of <em>C. difficile </em>infection on enterocyte integrity, rather than to a specific drug interaction.</p><p>A small study reported interactions between <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> and <a class="drug drug_general" data-topicid="9173" href="/z/d/drug information/9173.html" rel="external">busulfan</a>. Patients who received oral metronidazole as graft-versus-host disease prophylaxis in the setting of hematopoietic cell transplantation had significantly higher levels of busulfan than controls who received busulfan alone [<a href="#rid115">115</a>]. More adverse events were noted in the group of subjects receiving metronidazole and busulfan together (multiorgan failure, venoocclusive disease, and hemorrhagic cystitis), so the authors recommend avoiding administration of these agents together.</p><p>Hepatic enzyme inducers such as barbiturates, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a> can significantly reduce plasma concentrations of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> by increasing its clearance [<a href="#rid116">116</a>]. <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">Prednisone</a> may also enhance hepatic clearance of metronidazole [<a href="#rid117">117</a>]. These interactions can result in clinical failure of metronidazole therapy [<a href="#rid116">116</a>]. <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">Cimetidine</a> may increase serum metronidazole concentrations by inhibiting hepatic enzyme activity, but data regarding this interaction are conflicting [<a href="#rid118">118</a>]. Binding interactions with the gastrointestinal tract can also occur between metronidazole and aluminum- or magnesium-containing antacids, as well as <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a>. The interactions result in approximately 15 to 20 percent decreased bioavailability of metronidazole.</p><p>Coadministration of flavonoid extract of milk thistle, silymarin, can lead to increased clearance of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, possibly through silymarin induction of intestinal P-glycoprotein [<a href="#rid119">119</a>]. Thus, concomitant use of these agents should be avoided.</p><p>Additional information on drug interactions with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> can be found in the Lexicomp drug information monographs included within UpToDate. (See  <a class="drug drug_general" href="/z/d/drug information/9589.html" rel="external">"Metronidazole (systemic): Drug information"</a> and  <a class="drug drug_pediatric" href="/z/d/drug information/16019.html" rel="external">"Metronidazole (systemic): Pediatric drug information"</a> and  <a class="drug drug_general" href="/z/d/drug information/9590.html" rel="external">"Metronidazole (topical): Drug information"</a> and  <a class="drug drug_pediatric" href="/z/d/drug information/16018.html" rel="external">"Metronidazole (topical): Pediatric drug information"</a>.)</p><p class="headingAnchor" id="H21"><span class="h1">SPECIAL POPULATIONS</span></p><p class="headingAnchor" id="H22"><span class="h2">Pregnancy</span><span class="headingEndMark"> — </span>The use of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> in pregnancy is somewhat controversial. In general, use of metronidazole should be avoided, particularly during the first trimester [<a href="#rid120">120</a>]. It should only be used in pregnancy if treatment of infection is necessary and no safe alternative agents are available (eg, bacterial vaginosis, trichomoniasis) [<a href="#rid121">121</a>]. However, the United States Centers for Disease Control and Prevention suggests that treatment of bacterial vaginosis with short courses of metronidazole in pregnancy appears to pose a low risk of teratogenicity or mutagenic effects.</p><p>In general, some studies have shown a slightly increased risk of congenital abnormalities or preterm birth when mothers used <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, although data are conflicting. Although animal data suggest increased carcinogenesis, data in humans have not supported this observation. Representative data, according to outcome, are summarized below.</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital malformations – <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> crosses the placenta and rapidly enters the fetal circulation. Well-controlled studies are limited, and available data are conflicting. Concern for congenital malformations (eg, congenital hydrocephalus, cleft lip/palate) with the use of metronidazole during pregnancy was raised by two population-wide case control studies from the Hungarian Congenital Abnormality Registry. One study found that mothers of infants born with cleft lip/palate had a slightly higher rate of metronidazole use in the first trimester compared with mothers of infants born without cleft lip/palate (0.66 versus 0.53 percent) [<a href="#rid122">122</a>]. In the other study, vaginal metronidazole use during first trimester of pregnancy was associated with a slightly increased absolute risk of congenital hydrocephalus in infants [<a href="#rid123">123</a>]. Both studies, however, had a high recall bias. </p><p></p><p class="bulletIndent1">Subsequent cohort studies have not shown an increased risk of congenital malformations [<a href="#rid124">124,125</a>]. As an example, in a prospective cohort trial of 190 pregnant females exposed to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> (86.2 percent during first trimester) compared with 575 who were not exposed, there was no difference in the rate of major malformations between the two groups (1.6 versus 1.4 percent) [<a href="#rid125">125</a>]. In another retrospective study of 2829 singleton/mother pairs, 348 of whom were treated with metronidazole during first trimester of pregnancy, there was no association found between metronidazole treatment and congenital abnormalities (odds ratio 0.86, 95 CI 0.3 to 2.45) [<a href="#rid126">126</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Childhood cancers – Although <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is carcinogenic in rodents, studies in humans have not shown the same risk. In a retrospective cohort of 328,846 children under the age of five (8.1 percent of whom were exposed in utero to metronidazole), there was no difference in childhood cancers between the two groups [<a href="#rid127">127</a>]. However, the infrequent use of metronidazole in pregnancy and the rarity of childhood cancers makes it difficult to establish a causative effect.  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Preterm birth/low birth weight – <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> use during pregnancy is unlikely to be associated with preterm births or low birth weight in infants. Although a prospective study of 190 females exposed to metronidazole in pregnancy demonstrated a lower newborn birth weight (independent of gestational age at delivery) compared with females who were not exposed to metronidazole [<a href="#rid125">125</a>], subsequent studies did not corroborate this finding. In a retrospective study of 2829 singleton/mother pairs, 922 of whom received metronidazole treatment during pregnancy, there was no association between metronidazole use and preterm birth or low birth weight [<a href="#rid126">126</a>]. Furthermore, in a blinded, randomized controlled trial of over 2000 pregnant individuals who were randomized to antibiotics (metronidazole plus <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">erythromycin</a>) at 24 weeks of pregnancy or placebo for the prevention of preterm births, there was no difference in mean gestational age at delivery, percentage of preterm births, or birthweight between the two groups [<a href="#rid128">128</a>]. </p><p></p><p class="headingAnchor" id="H23"><span class="h2">Nursing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is excreted in the breast milk after systemic administration at concentrations similar to those in the serum. Its half-life in breast milk is approximately 9 to 10 hours. Thus, it is recommended that nursing be discontinued during and for three days after metronidazole therapy.</p><p class="headingAnchor" id="H24"><span class="h2">Hemodialysis/chronic ambulatory peritoneal dialysis</span><span class="headingEndMark"> — </span>Although <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> is significantly removed by hemodialysis, no specific dose recommendations are made for this patient population. Dose modifications are not recommended for patients undergoing chronic ambulatory peritoneal dialysis.</p><p class="headingAnchor" id="H25"><span class="h2">Renal/hepatic dysfunction</span><span class="headingEndMark"> — </span>No specific dose adjustments are recommended for patients with renal or hepatic dysfunction receiving <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>. However, since accumulation of the drug and its metabolites can occur in those with hepatic dysfunction, lower doses may be considered based upon severity of illness and patient tolerability. Doses of 500 mg intravenously once or twice daily have been recommended for patients with severe liver failure [<a href="#rid27">27,67,129</a>].</p><p class="headingAnchor" id="H1051243296"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectrum of activity</strong> − <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> is one of the mainstay drugs for the treatment of anaerobic infections. It is approved by the US Food and Drug Administration for the treatment of anaerobic and protozoal infections. (See <a class="local">'Introduction'</a> above and <a class="local">'Spectrum of activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanism of action</strong> − The mechanism of action of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> against obligate anaerobes occurs through a four-step process that includes entry into the organism, reductive activation by intracellular transport proteins, interactions with intracellular targets, and breakdown of cytotoxic-intermediate products. Metronidazole is also cytotoxic to facultative anaerobic bacteria such as <em>Helicobacter pylori</em> and <em>Gardnerella vaginalis</em>, but the mechanism of action against these organisms is not well understood. (See <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance</strong> − Despite extensive worldwide use, acquired resistance to <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> among anaerobic bacteria is rare. Resistance to metronidazole has been reported more frequently with <em>H. pylori</em>. (See <a class="local">'Resistance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacokinetics</strong> − Two of the hallmarks of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> are that the drug achieves high serum concentrations following oral administration and that its tissue penetration is excellent. Metronidazole generally distributes well into body tissues and, unlike <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">clindamycin</a>, effectively penetrates the blood-brain barrier. (See <a class="local">'Pharmacokinetics'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Toxicity</strong> − The most common adverse effects associated with systemic <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> therapy are gastrointestinal (eg, nausea, anorexia, vomiting, diarrhea, abdominal cramping, constipation). Metronidazole can also cause nervous system effects (eg, peripheral neuropathy, confusion, dizziness). Metronidazole has also been associated with hypersensitivity reactions. (See <a class="local">'Toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug interactions </strong>− Most drug interactions with <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> occur in the liver, where metronidazole is metabolized. It has been suggested that metronidazole selectively inhibits aromatic oxidase reactions in the liver, a property that may explain its inhibition of <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, and <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">carbamazepine</a> metabolism. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ingestion of alcohol during <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a> therapy (administered orally or vaginally) can result in a disulfiram-like reaction characterized by flushing, tachycardia, palpitations, nausea, and vomiting. Ethanol-containing medications such as elixirs as well as <a class="drug drug_general" data-topicid="9459" href="/z/d/drug information/9459.html" rel="external">tipranavir</a> capsules, intravenous <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, and many cough/cold syrups can also lead to a disulfiram-like reaction when ingested with metronidazole. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> can promote renal retention of <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">lithium</a>, resulting in increased lithium levels and lithium toxicity. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> can also decrease elimination of ergot derivatives, so concomitant use of these agents is not recommended. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Agents that induce hepatic enzymes, such as barbiturates, <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">rifampin</a>, can reduce levels of <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>. These interactions have been associated with clinical failure of metronidazole. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use in pregnancy</strong> − <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">Metronidazole</a> should only be used during pregnancy if treatment of infection is necessary and no safe alternative agents are available (eg, bacterial vaginosis, trichomoniasis). (See <a class="local">'Pregnancy'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 2010; 50 Suppl 1:S16.</a></li><li><a class="nounderline abstract_t">Dingsdag SA, Hunter N. Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms. J Antimicrob Chemother 2018; 73:265.</a></li><li><a class="nounderline abstract_t">Edwards DI. Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 1993; 31:9.</a></li><li><a class="nounderline abstract_t">Edwards DI. Reduction of nitroimidazoles in vitro and DNA damage. Biochem Pharmacol 1986; 35:53.</a></li><li><a class="nounderline abstract_t">Müller M. Reductive activation of nitroimidazoles in anaerobic microorganisms. Biochem Pharmacol 1986; 35:37.</a></li><li><a class="nounderline abstract_t">Tocher JH, Edwards DI. The interaction of reduced metronidazole with DNA bases and nucleosides. Int J Radiat Oncol Biol Phys 1992; 22:661.</a></li><li><a class="nounderline abstract_t">Tocher JH, Edwards DI. Evidence for the direct interaction of reduced metronidazole derivatives with DNA bases. Biochem Pharmacol 1994; 48:1089.</a></li><li><a class="nounderline abstract_t">Goldman P, Koch RL, Yeung TC, et al. Comparing the reduction of nitroimidazoles in bacteria and mammalian tissues and relating it to biological activity. Biochem Pharmacol 1986; 35:43.</a></li><li><a class="nounderline abstract_t">Stratton CW, Weeks LS, Aldridge KE. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Diagn Microbiol Infect Dis 1991; 14:377.</a></li><li><a class="nounderline abstract_t">Stratton CW, Weeks LS, Aldridge KE. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Diagn Microbiol Infect Dis 1992; 15:321.</a></li><li><a class="nounderline abstract_t">Ravdin JI, Skilogiannis J. In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole. Antimicrob Agents Chemother 1989; 33:960.</a></li><li><a class="nounderline abstract_t">Nix DE, Tyrrell R, Müller M. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis. Antimicrob Agents Chemother 1995; 39:1848.</a></li><li><a class="nounderline abstract_t">Ralph ED, Kirby WM. Unique bactericidal action of metronidazole against Bacteroides fragilis and Clostridium perfringens. Antimicrob Agents Chemother 1975; 8:409.</a></li><li><a class="nounderline abstract_t">Ralph ED, Amatnieks YE. Potentially synergistic antimicrobial combinations with metronidazole against Bacteroides fragilis. Antimicrob Agents Chemother 1980; 17:379.</a></li><li><a class="nounderline abstract_t">Cuchural GJ Jr, Tally FP, Jacobus NV, et al. Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982. Antimicrob Agents Chemother 1984; 26:145.</a></li><li><a class="nounderline abstract_t">Musial CE, Rosenblatt JE. Antimicrobial susceptibilities of anaerobic bacteria isolated at the Mayo Clinic during 1982 through 1987: comparison with results from 1977 through 1981. Mayo Clin Proc 1989; 64:392.</a></li><li><a class="nounderline abstract_t">Snydman DR, Jacobus NV, McDermott LA, et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother 1999; 43:2417.</a></li><li><a class="nounderline abstract_t">Aldridge KE, Ashcraft D, O'Brien M, Sanders CV. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns. Antimicrob Agents Chemother 2003; 47:148.</a></li><li><a class="nounderline abstract_t">Snydman DR, Jacobus NV, McDermott LA, et al. Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007). Clin Infect Dis 2010; 50 Suppl 1:S26.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Multidrug-resistant bacteroides fragilis--Seattle, Washington, 2013. MMWR Morb Mortal Wkly Rep 2013; 62:694.</a></li><li><a class="nounderline abstract_t">Merchan C, Parajuli S, Siegfried J, et al. Multidrug-Resistant Bacteroides fragilis Bacteremia in a US Resident: An Emerging Challenge. Case Rep Infect Dis 2016; 2016:3607125.</a></li><li><a class="nounderline abstract_t">Sherwood JE, Fraser S, Citron DM, et al. Multi-drug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan. Anaerobe 2011; 17:152.</a></li><li><a class="nounderline abstract_t">Sethi S, Shukla R, Bala K, et al. Emerging metronidazole resistance in Bacteroides spp. and its association with the nim gene: a study from North India. J Glob Antimicrob Resist 2019; 16:210.</a></li><li><a class="nounderline abstract_t">Brazier JS, Stubbs SL, Duerden BI. Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group: time to be concerned? J Antimicrob Chemother 1999; 44:580.</a></li><li><a class="nounderline abstract_t">Barbut F, Decré D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999; 43:2607.</a></li><li><a class="nounderline abstract_t">Reysset G, Haggoud A, Sebald M. Genetics of resistance of Bacteroides species to 5-nitroimidazole. Clin Infect Dis 1993; 16 Suppl 4:S401.</a></li><li><a class="nounderline abstract_t">Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance in Bacteroides. Clin Infect Dis 1993; 16 Suppl 4:S390.</a></li><li><a class="nounderline abstract_t">Narikawa S, Suzuki T, Yamamoto M, Nakamura M. Lactate dehydrogenase activity as a cause of metronidazole resistance in Bacteroides fragilis NCTC 11295. J Antimicrob Chemother 1991; 28:47.</a></li><li><a class="nounderline abstract_t">Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11:777.</a></li><li><a class="nounderline abstract_t">Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. Am J Gastroenterol 1998; 93:386.</a></li><li><a class="nounderline abstract_t">Ho JJC, Navarro M, Sawyer K, et al. Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis. Am J Gastroenterol 2022; 117:1221.</a></li><li><a class="nounderline abstract_t">Saranathan R, Levi MH, Wattam AR, et al. Helicobacter pylori Infections in the Bronx, New York: Surveying Antibiotic Susceptibility and Strain Lineage by Whole-Genome Sequencing. J Clin Microbiol 2020; 58.</a></li><li><a class="nounderline abstract_t">Lacey SL, Moss SF, Taylor GW. Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori. J Antimicrob Chemother 1993; 32:393.</a></li><li><a class="nounderline abstract_t">Moore RA, Beckthold B, Bryan LE. Metronidazole uptake in Helicobacter pylori. Can J Microbiol 1995; 41:746.</a></li><li><a class="nounderline abstract_t">Lee SM, Kim N, Kwon YH, et al. rdxA, frxA, and efflux pump in metronidazole-resistant Helicobacter pylori: Their relation to clinical outcomes. J Gastroenterol Hepatol 2018; 33:681.</a></li><li><a class="nounderline abstract_t">Logan RP, Gummett PA, Misiewicz JJ, et al. One week eradication regimen for Helicobacter pylori. Lancet 1991; 338:1249.</a></li><li><a class="nounderline abstract_t">Owen RJ, Bell GD, Desai M, et al. Biotype and molecular fingerprints of metronidazole-resistant strains of Helicobacter pylori from antral gastric mucosa. J Med Microbiol 1993; 38:6.</a></li><li><a class="nounderline abstract_t">Wong WM, Gu Q, Wang WH, et al. Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance. Clin Infect Dis 2003; 37:882.</a></li><li><a class="nounderline abstract_t">Dore MP, Leandro G, Realdi G, et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45:68.</a></li><li><a class="nounderline abstract_t">Krajden S, Lossick JG, Wilk E, et al. Persistent Trichomonas vaginalis infection due to a metronidazole-resistant strain. CMAJ 1986; 134:1373.</a></li><li><a class="nounderline abstract_t">Müller M, Meingassner JG, Miller WA, Ledger WJ. Three metronidazole-resistant strains of Trichomonas vaginalis from the United States. Am J Obstet Gynecol 1980; 138:808.</a></li><li><a class="nounderline abstract_t">Dombrowski MP, Sokol RJ, Brown WJ, Bronsteen RA. Intravenous therapy of metronidazole-resistant Trichomonas vaginalis. Obstet Gynecol 1987; 69:524.</a></li><li><a class="nounderline abstract_t">Kulda J. Trichomonads, hydrogenosomes and drug resistance. Int J Parasitol 1999; 29:199.</a></li><li><a class="nounderline abstract_t">Edwards DI. Nitroimidazole drugs--action and resistance mechanisms. II. Mechanisms of resistance. J Antimicrob Chemother 1993; 31:201.</a></li><li><a class="nounderline abstract_t">Quon DV, d'Oliveira CE, Johnson PJ. Reduced transcription of the ferredoxin gene in metronidazole-resistant Trichomonas vaginalis. Proc Natl Acad Sci U S A 1992; 89:4402.</a></li><li><a class="nounderline abstract_t">Nguyen MH, Yu VL, Morris AJ, et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000; 30:870.</a></li><li><a class="nounderline abstract_t">Baron EJ, Ropers G, Summanen P, Courcol RJ. Bactericidal activity of selected antimicrobial agents against Bilophila wadsworthia and Bacteroides gracilis. Clin Infect Dis 1993; 16 Suppl 4:S339.</a></li><li><a class="nounderline abstract_t">Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin. Antimicrob Agents Chemother 1993; 37:1649.</a></li><li><a class="nounderline abstract_t">Sheikh W, Pitkin DH, Nadler H. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers. Clin Infect Dis 1993; 16 Suppl 4:S361.</a></li><li><a class="nounderline abstract_t">Alexander CJ, Citron DM, Brazier JS, Goldstein EJ. Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens. J Clin Microbiol 1995; 33:3209.</a></li><li><a class="nounderline abstract_t">Brazier JS, Levett PN, Stannard AJ, et al. Antibiotic susceptibility of clinical isolates of clostridia. J Antimicrob Chemother 1985; 15:181.</a></li><li><a class="nounderline abstract_t">Goldstein EJ, Citron DM, Cherubin CE, Hillier SL. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother 1993; 31:363.</a></li><li><a class="nounderline abstract_t">Jones BM, Geary I, Lee ME, Duerden BI. Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections. Antimicrob Agents Chemother 1989; 33:970.</a></li><li><a class="nounderline abstract_t">Spiegel CA. Susceptibility of Mobiluncus species to 23 antimicrobial agents and 15 other compounds. Antimicrob Agents Chemother 1987; 31:249.</a></li><li><a class="nounderline abstract_t">Bannatyne RM, Jackowski J, Cheung R, Biers K. Susceptibility of Gardnerella vaginalis to metronidazole, its bioactive metabolites, and tinidazole. Am J Clin Pathol 1987; 87:640.</a></li><li><a class="nounderline abstract_t">Easmon CS, Ison CA, Kaye CM, et al. Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis. Br J Vener Dis 1982; 58:246.</a></li><li><a class="nounderline abstract_t">Lau AH, Lam NP, Piscitelli SC, et al. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23:328.</a></li><li><a class="nounderline abstract_t">Jokipii AM, Myllylä VV, Hokkanen E, Jokipii L. Penetration of the blood brain barrier by metronidazole and tinidazole. J Antimicrob Chemother 1977; 3:239.</a></li><li><a class="nounderline abstract_t">Warner JF, Perkins RL, Cordero L. Metronidazole therapy of anaerobic bacteremia, meningitis, and brain abscess. Arch Intern Med 1979; 139:167.</a></li><li><a class="nounderline abstract_t">Karjagin J, Pähkla R, Karki T, Starkopf J. Distribution of metronidazole in muscle tissue of patients with septic shock and its efficacy against Bacteroides fragilis in vitro. J Antimicrob Chemother 2005; 55:341.</a></li><li><a class="nounderline abstract_t">Karjagin J, Pähkla R, Starkopf J. Perioperative penetration of metronidazole into muscle tissue: a microdialysis study. Eur J Clin Pharmacol 2004; 59:809.</a></li><li><a class="nounderline abstract_t">Nielsen ML, Justesen T. Excretion of metroindazole in human bile. Investigations of hepatic bile, common duct bile, and gallbladder bile. Scand J Gastroenterol 1977; 12:1003.</a></li><li><a class="nounderline abstract_t">Jensen JC, Gugler R. Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther 1983; 34:481.</a></li><li><a class="nounderline abstract_t">Kreeft JH, Ogilvie RI, Dufresne LR. Metronidazole kinetics in dialysis patients. Surgery 1983; 93:149.</a></li><li><a class="nounderline abstract_t">Lau AH, Chang CW, Sabatini S. Hemodialysis clearance of metronidazole and its metabolites. Antimicrob Agents Chemother 1986; 29:235.</a></li><li><a class="nounderline abstract_t">Roux AF, Moirot E, Delhotal B, et al. Metronidazole kinetics in patients with acute renal failure on dialysis: a cumulative study. Clin Pharmacol Ther 1984; 36:363.</a></li><li><a class="nounderline abstract_t">Somogyi A, Kong C, Sabto J, et al. Disposition and removal of metronidazole in patients undergoing haemodialysis. Eur J Clin Pharmacol 1983; 25:683.</a></li><li><a class="nounderline abstract_t">Guay DR, Meatherall RC, Baxter H, et al. Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1984; 25:306.</a></li><li><a class="nounderline abstract_t">Farrell G, Baird-Lambert J, Cvejic M, Buchanan N. Disposition and metabolism of metronidazole in patients with liver failure. Hepatology 1984; 4:722.</a></li><li><a class="nounderline abstract_t">Farrell G, Buchanan N, Baird-Lambert J. Impaired elimination of metronidazole in decompensated chronic liver disease. Br Med J (Clin Res Ed) 1984; 288:1009.</a></li><li><a class="nounderline abstract_t">Daneshmend TK, Roberts CJ. Impaired elimination of metronidazole in decompensated chronic liver disease. Br Med J (Clin Res Ed) 1984; 288:405.</a></li><li><a class="nounderline abstract_t">Plaisance KI, Quintiliani R, Nightingale CH. The pharmacokinetics of metronidazole and its metabolites in critically ill patients. J Antimicrob Chemother 1988; 21:195.</a></li><li><a class="nounderline abstract_t">Lau AH, Evans R, Chang CW, Seligsohn R. Pharmacokinetics of metronidazole in patients with alcoholic liver disease. Antimicrob Agents Chemother 1987; 31:1662.</a></li><li><a class="nounderline abstract_t">Upadhyaya P, Bhatnagar V, Basu N. Pharmacokinetics of intravenous metronidazole in neonates. J Pediatr Surg 1988; 23:263.</a></li><li><a class="nounderline abstract_t">Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ. Central nervous system toxicity associated with metronidazole therapy. Ann Intern Med 1980; 93:59.</a></li><li><a class="nounderline abstract_t">Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999; 36:353.</a></li><li><a class="nounderline abstract_t">Urtasun RC, Rabin HR, Partington J. Human pharmacokinetics and toxicity of high-dose metronidazole administered orally and intravenously. Surgery 1983; 93:145.</a></li><li><a class="nounderline abstract_t">Saginur R, Hawley CR, Bartlett JG. Colitis associated with metronidazole therapy. J Infect Dis 1980; 141:772.</a></li><li><a class="nounderline abstract_t">Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 1978; 88:361.</a></li><li><a class="nounderline abstract_t">Halloran TJ. Convulsions associated with high cumulative doses of metronidazole. Drug Intell Clin Pharm 1982; 16:409.</a></li><li><a class="nounderline abstract_t">Soule AF, Green SB, Blanchette LM. Clinical efficacy of 12-h metronidazole dosing regimens in patients with anaerobic or mixed anaerobic infections. Ther Adv Infect Dis 2018; 5:57.</a></li><li><a class="nounderline abstract_t">Shah S, Adams K, Merwede J, et al. Three is a crowd: Clinical outcomes of a twice daily versus a thrice daily metronidazole dosing strategy from a multicenter study. Anaerobe 2021; 71:102378.</a></li><li><a class="nounderline abstract_t">Sprandel KA, Drusano GL, Hecht DW, et al. Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagn Microbiol Infect Dis 2006; 55:303.</a></li><li><a class="nounderline abstract_t">Farmakiotis D, Zeluff B. IMAGES IN CLINICAL MEDICINE. Metronidazole-Associated Encephalopathy. N Engl J Med 2016; 374:1465.</a></li><li><a class="nounderline abstract_t">Lefkowitz A, Shadowitz S. Reversible cerebellar neurotoxicity induced by metronidazole. CMAJ 2018; 190:E961.</a></li><li><a class="nounderline abstract_t">Daneman N, Cheng Y, Gomes T, et al. Metronidazole-associated Neurologic Events: A Nested Case-control Study. Clin Infect Dis 2021; 72:2095.</a></li><li><a class="nounderline abstract_t">Kim E, Na DG, Kim EY, et al. MR imaging of metronidazole-induced encephalopathy: lesion distribution and diffusion-weighted imaging findings. AJNR Am J Neuroradiol 2007; 28:1652.</a></li><li><a class="nounderline abstract_t">Carroll MW, Jeon D, Mountz JM, et al. Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2013; 57:3903.</a></li><li><a class="nounderline abstract_t">Knowles S, Choudhury T, Shear NH. Metronidazole hypersensitivity. Ann Pharmacother 1994; 28:325.</a></li><li><a class="nounderline abstract_t">Cina SJ, Russell RA, Conradi SE. Sudden death due to metronidazole/ethanol interaction. Am J Forensic Med Pathol 1996; 17:343.</a></li><li><a class="nounderline abstract_t">Williams CS, Woodcock KR. Do ethanol and metronidazole interact to produce a disulfiram-like reaction? Ann Pharmacother 2000; 34:255.</a></li><li><a class="nounderline abstract_t">Alexander I. 'Alcohol-antabuse' syndrome in patients receiving metronidazole during gynaecological treatment. Br J Clin Pract 1985; 39:292.</a></li><li><a class="nounderline abstract_t">Plosker GL. Possible interaction between ethanol and vaginally administered metronidazole. Clin Pharm 1987; 6:189, 192.</a></li><li><a class="nounderline abstract_t">Visapää JP, Tillonen JS, Kaihovaara PS, Salaspuro MP. Lack of disulfiram-like reaction with metronidazole and ethanol. Ann Pharmacother 2002; 36:971.</a></li><li><a class="nounderline abstract_t">Tillonen J, Väkeväinen S, Salaspuro V, et al. Metronidazole increases intracolonic but not peripheral blood acetaldehyde in chronic ethanol-treated rats. Alcohol Clin Exp Res 2000; 24:570.</a></li><li><a class="nounderline abstract_t">McKendrick MW, Geddes AM. Neutropenia associated with metronidazole. Br Med J 1979; 2:795.</a></li><li><a class="nounderline abstract_t">Smith JA. Neutropenia associated with metronidazole therapy. Can Med Assoc J 1980; 123:202.</a></li><li><a class="nounderline abstract_t">Celifarco A, Warschauer C, Burakoff R. Metronidazole-induced pancreatitis. Am J Gastroenterol 1989; 84:958.</a></li><li><a class="nounderline abstract_t">Sanford KA, Mayle JE, Dean HA, Greenbaum DS. Metronidazole-associated pancreatitis. Ann Intern Med 1988; 109:756.</a></li><li><a class="nounderline abstract_t">Altın C, Kanyılmaz S, Baysal S, Özin B. QT interval prolongation due to metronidazole administration. Anadolu Kardiyol Derg 2011; 11:468.</a></li><li><a class="nounderline abstract_t">Cohen O, Saar N, Swartzon M, et al. First report of metronidazole-induced QT interval prolongation. Int J Antimicrob Agents 2008; 31:180.</a></li><li><a class="nounderline abstract_t">Poluzzi E, Raschi E, Motola D, et al. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf 2010; 33:303.</a></li><li><a class="nounderline abstract_t">Powell SJ. The cardiotoxicity of systemic amebicides. A comparative electrocardiographic study. Am J Trop Med Hyg 1967; 16:447.</a></li><li><a class="nounderline abstract_t">Teicher MH, Altesman RI, Cole JO, Schatzberg AF. Possible nephrotoxic interaction of lithium and metronidazole. JAMA 1987; 257:3365.</a></li><li><a class="nounderline abstract_t">Lassen E. Effects of acute and short-time antibiotic treatment on renal lithium elimination and serum lithium levels in the rat. Acta Pharmacol Toxicol (Copenh) 1985; 56:273.</a></li><li><a class="nounderline abstract_t">Blyden GT, Scavone JM, Greenblatt DJ. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. J Clin Pharmacol 1988; 28:240.</a></li><li><a class="nounderline abstract_t">O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976; 295:354.</a></li><li><a class="nounderline abstract_t">Patterson BD. Possible interaction between metronidazole and carbamazepine. Ann Pharmacother 1994; 28:1303.</a></li><li><a class="nounderline abstract_t">Kounas SP, Letsas KP, Sideris A, et al. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone. Pacing Clin Electrophysiol 2005; 28:472.</a></li><li><a class="nounderline abstract_t">Panduranga P, Al-Mukhaini M, Rajarao MP. Multi-factorial causes of torsade de pointes in a hospitalised surgical patient. Sultan Qaboos Univ Med J 2013; 13:152.</a></li><li><a class="nounderline abstract_t">Zylber-Katz E, Rubinger D, Berlatzky Y. Cyclosporine interactions with metronidazole and cimetidine. Drug Intell Clin Pharm 1988; 22:504.</a></li><li><a class="nounderline abstract_t">Herzig K, Johnson DW. Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy. Nephrol Dial Transplant 1999; 14:521.</a></li><li><a class="nounderline abstract_t">Page RL 2nd, Klem PM, Rogers C. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. Ann Pharmacother 2005; 39:1109.</a></li><li><a class="nounderline abstract_t">Early CR, Park JM, Dorsch MP, et al. Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for Clostridium difficile. Transpl Infect Dis 2016; 18:714.</a></li><li><a class="nounderline abstract_t">Nilsson C, Aschan J, Hentschke P, et al. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31:429.</a></li><li><a class="nounderline abstract_t">Eradiri O, Jamali F, Thomson AB. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. Biopharm Drug Dispos 1988; 9:219.</a></li><li><a class="nounderline abstract_t">Mead PB, Gibson M, Schentag JJ, Ziemniak JA. Possible alteration of metronidazole metabolism by phenobarbital. N Engl J Med 1982; 306:1490.</a></li><li><a class="nounderline abstract_t">Loft S, Døssing M, Sonne J, et al. Lack of effect of cimetidine on the pharmacokinetics and metabolism of a single oral dose of metronidazole. Eur J Clin Pharmacol 1988; 35:65.</a></li><li><a class="nounderline abstract_t">Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 2004; 54:109.</a></li><li class="breakAll">Gerald G. Birggs, Roger K. Freeman, Craig V. Towers, Alicia B. Forinash. Metronidazole. In: Drugs in Pregnancy and Lactation 12th Edition: A Reference Guide to Fetal and Neonatal Risk, 2021.</li><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole treatment during pregnancy. Br J Obstet Gynaecol 1998; 105:322.</a></li><li><a class="nounderline abstract_t">Kazy Z, Puhó E, Czeizel AE. Teratogenic potential of vaginal metronidazole treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2005; 123:174.</a></li><li><a class="nounderline abstract_t">Sørensen HT, Larsen H, Jensen ES, et al. Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women. J Antimicrob Chemother 1999; 44:854.</a></li><li><a class="nounderline abstract_t">Diav-Citrin O, Shechtman S, Gotteiner T, et al. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. Teratology 2001; 63:186.</a></li><li><a class="nounderline abstract_t">Koss CA, Baras DC, Lane SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. Antimicrob Agents Chemother 2012; 56:4800.</a></li><li><a class="nounderline abstract_t">Thapa PB, Whitlock JA, Brockman Worrell KG, et al. Prenatal exposure to metronidazole and risk of childhood cancer: a retrospective cohort study of children younger than 5 years. Cancer 1998; 83:1461.</a></li><li><a class="nounderline abstract_t">Goldenberg RL, Mwatha A, Read JS, et al. The HPTN 024 Study: The efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol 2006; 194:650.</a></li><li><a class="nounderline abstract_t">Loft S, Sonne J, Døssing M, Andreasen PB. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 1987; 22:117.</a></li></ol></div><div id="topicVersionRevision">Topic 464 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20067388" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Metronidazole is still the drug of choice for treatment of anaerobic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29077920" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8444678" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3940526" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Reduction of nitroimidazoles in vitro and DNA damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3940525" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Reductive activation of nitroimidazoles in anaerobic microorganisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1544834" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The interaction of reduced metronidazole with DNA bases and nucleosides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7945401" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evidence for the direct interaction of reduced metronidazole derivatives with DNA bases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3753580" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparing the reduction of nitroimidazoles in bacteria and mammalian tissues and relating it to biological activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1797454" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1611847" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2548442" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7486930" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/172007" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Unique bactericidal action of metronidazole against Bacteroides fragilis and Clostridium perfringens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6448574" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Potentially synergistic antimicrobial combinations with metronidazole against Bacteroides fragilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6486758" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2716353" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antimicrobial susceptibilities of anaerobic bacteria isolated at the Mayo Clinic during 1982 through 1987: comparison with results from 1977 through 1981.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10508018" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12499183" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20067390" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005-2007).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23985497" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Multidrug-resistant bacteroides fragilis--Seattle, Washington, 2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418986" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Multidrug-Resistant Bacteroides fragilis Bacteremia in a US Resident: An Emerging Challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21376821" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Multi-drug resistant Bacteroides fragilis recovered from blood and severe leg wounds caused by an improvised explosive device (IED) in Afghanistan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30342928" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Emerging metronidazole resistance in Bacteroides spp. and its association with the nim gene: a study from North India.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10588328" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group: time to be concerned?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10543736" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8324155" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Genetics of resistance of Bacteroides species to 5-nitroimidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8324154" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Antimicrobial resistance in Bacteroides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1769942" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lactate dehydrogenase activity as a cause of metronidazole resistance in Bacteroides fragilis NCTC 11295.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1468415" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9517645" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35509128" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31801839" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Helicobacter pylori Infections in the Bronx, New York: Surveying Antibiotic Susceptibility and Strain Lineage by Whole-Genome Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8262861" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7553456" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Metronidazole uptake in Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28748532" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : rdxA, frxA, and efflux pump in metronidazole-resistant Helicobacter pylori: Their relation to clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1682653" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : One week eradication regimen for Helicobacter pylori.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8418295" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Biotype and molecular fingerprints of metronidazole-resistant strains of Helicobacter pylori from antral gastric mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13130398" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10695616" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3486706" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Persistent Trichomonas vaginalis infection due to a metronidazole-resistant strain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7004190" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Three metronidazole-resistant strains of Trichomonas vaginalis from the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3492696" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Intravenous therapy of metronidazole-resistant Trichomonas vaginalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10221623" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Trichomonads, hydrogenosomes and drug resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8463167" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nitroimidazole drugs--action and resistance mechanisms. II. Mechanisms of resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1374901" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Reduced transcription of the ferredoxin gene in metronidazole-resistant Trichomonas vaginalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852736" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8324144" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bactericidal activity of selected antimicrobial agents against Bilophila wadsworthia and Bacteroides gracilis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8215278" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8324148" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8586704" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3872295" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Antibiotic susceptibility of clinical isolates of clostridia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8486570" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2764547" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3566250" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Susceptibility of Mobiluncus species to 23 antimicrobial agents and 15 other compounds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3495168" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Susceptibility of Gardnerella vaginalis to metronidazole, its bioactive metabolites, and tinidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6980684" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1478003" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/873873" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Penetration of the blood brain barrier by metronidazole and tinidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/434970" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Metronidazole therapy of anaerobic bacteremia, meningitis, and brain abscess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15728145" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Distribution of metronidazole in muscle tissue of patients with septic shock and its efficacy against Bacteroides fragilis in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14586529" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Perioperative penetration of metronidazole into muscle tissue: a microdialysis study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/605347" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Excretion of metroindazole in human bile. Investigations of hepatic bile, common duct bile, and gallbladder bile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6617070" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Single- and multiple-dose metronidazole kinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6849199" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Metronidazole kinetics in dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3717930" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Hemodialysis clearance of metronidazole and its metabolites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6467795" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Metronidazole kinetics in patients with acute renal failure on dialysis: a cumulative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6662167" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Disposition and removal of metronidazole in patients undergoing haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6721462" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6745863" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Disposition and metabolism of metronidazole in patients with liver failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6423154" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Impaired elimination of metronidazole in decompensated chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6419944" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Impaired elimination of metronidazole in decompensated chronic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3360682" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The pharmacokinetics of metronidazole and its metabolites in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3435113" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pharmacokinetics of metronidazole in patients with alcoholic liver disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3357144" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pharmacokinetics of intravenous metronidazole in neonates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7396319" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Central nervous system toxicity associated with metronidazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10384859" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6849198" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Human pharmacokinetics and toxicity of high-dose metronidazole administered orally and intravenously.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7391617" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Colitis associated with metronidazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/629500" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Neurologic toxicity associated with high-dose metronidazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7084034" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Convulsions associated with high cumulative doses of metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29796265" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Clinical efficacy of 12-h metronidazole dosing regimens in patients with anaerobic or mixed anaerobic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33965559" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Three is a crowd: Clinical outcomes of a twice daily versus a thrice daily metronidazole dosing strategy from a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16887471" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27074069" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : IMAGES IN CLINICAL MEDICINE. Metronidazole-Associated Encephalopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30104190" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Reversible cerebellar neurotoxicity induced by metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32303736" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Metronidazole-associated Neurologic Events: A Nested Case-control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17885234" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : MR imaging of metronidazole-induced encephalopathy: lesion distribution and diffusion-weighted imaging findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23733467" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Efficacy and safety of metronidazole for pulmonary multidrug-resistant tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8193418" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Metronidazole hypersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8947362" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Sudden death due to metronidazole/ethanol interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10676835" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Do ethanol and metronidazole interact to produce a disulfiram-like reaction?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4027157" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : 'Alcohol-antabuse' syndrome in patients receiving metronidazole during gynaecological treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3665375" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Possible interaction between ethanol and vaginally administered metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12022894" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Lack of disulfiram-like reaction with metronidazole and ethanol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10798595" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Metronidazole increases intracolonic but not peripheral blood acetaldehyde in chronic ethanol-treated rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/519201" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Neutropenia associated with metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7260762" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Neutropenia associated with metronidazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2756988" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Metronidazole-induced pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3263823" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Metronidazole-associated pancreatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21733783" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : QT interval prolongation due to metronidazole administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18082376" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : First report of metronidazole-induced QT interval prolongation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20297862" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4952146" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The cardiotoxicity of systemic amebicides. A comparative electrocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3586264" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Possible nephrotoxic interaction of lithium and metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4024954" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Effects of acute and short-time antibiotic treatment on renal lithium elimination and serum lithium levels in the rat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3360972" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/934223" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The stereoselective interaction of warfarin and metronidazole in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7849350" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Possible interaction between metronidazole and carbamazepine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15869686" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23573398" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Multi-factorial causes of torsade de pointes in a hospitalised surgical patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3293960" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Cyclosporine interactions with metronidazole and cimetidine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10069238" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15855244" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27501504" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Effect of metronidazole use on tacrolimus concentrations in transplant patients treated for Clostridium difficile.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12665836" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2897213" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7078600" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Possible alteration of metronidazole metabolism by phenobarbital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3220096" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Lack of effect of cimetidine on the pharmacokinetics and metabolism of a single oral dose of metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15038460" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15038460" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9532994" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : A population based case-control teratologic study of oral metronidazole treatment during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16316810" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Teratogenic potential of vaginal metronidazole treatment during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10590296" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11320529" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22751543" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Investigation of metronidazole use during pregnancy and adverse birth outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9762949" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Prenatal exposure to metronidazole and risk of childhood cancer: a retrospective cohort study of children younger than 5 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16522393" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : The HPTN 024 Study: The efficacy of antibiotics to prevent chorioamnionitis and preterm birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3563404" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Metronidazole pharmacokinetics in patients with hepatic encephalopathy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
